10.1152/ajpregu.00479.2002 Am
Annals of Internal Medicine
dulaglutide, NEJM, 2025 Semaglutide and cartilage regeneration Cell Metabolism, 2026 Lean mass loss with GLP-1 drugs systematic review, 2024 Retatrutide Phase 2 NEJM, 2023 Myostatin gene discovery McPherron et al., Nature, 1997 German myostatin-knockout child Schuelke et al., NEJM, 2004 Myostatin inhibitor history Nielsen et al., Cells, 2021 Micronutrient joint advisory Mozaffarian et al., 2025 Last Updated on June 20, 2026 by Joe Garma
Novo Nordisk Press Release: Advances early-stage obesity medication, amycretin, to Phase 3 clinical development
For many people, this can make the weight loss process feel more manageable and less restrictive
It was later approved in November 2023 as Zepbound for obesity treatment